



Handwritten: #191, 11/21/01, and a circled signature.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
NOV 15 2001
TECH CENTER 1600/2900

Applicant : Mark Parrington et al
Appl'n. No. : 09/190,246
Filed : November 13, 1998
Title : ALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES
Grp./A.U. : 1633
Examiner : M. Wilson
Docket No. : 1038-865 MIS:jb

October 30, 2001

BY COURIER

The Commissioner of Patents
and Trademarks,
Box AF
Washington, D.C. 20231,
U.S.A.

AMENDMENT AFTER FINAL ACTION
(Response Under 37 CFR 1.116 - Expedited Procedure)

Sir:

In response to the Office Action of May 5, 2001, please amend the
above-identified application as follows:

In the Claims:

Please cancel claims 7, 11, 12 and 13.

Claims 1, 14, 15 and 36 have been amended as follows:

1. (Twice Amended) A vector, comprising:

a first DNA sequence which is complementary to at least part of an alphavirus
RNA genome and having the complement of complete alphavirus RNA genome
replication regions that permits *in vivo* replication;

a second DNA sequence encoding a respiratory syncytial virus (RSV) protein
selected from the group consisting of the F and G glycoprotein of RSV or encoding a
protein fragment that induces production of antibodies that specifically react with the
RSV protein, said protein fragment being a truncated RSV F or RSV G protein